USP15 antagonizes CRL4CRBN-mediated ubiquitylation of glutamine synthetase and neosubstrates

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 118; no. 40; pp. 1 - 8
• Main Author: Van Nguyen, Thang
• Format: Journal Article
• Language: English
• Published: Washington National Academy of Sciences 05.10.2021
• Subjects: Anticancer properties; Antitumor activity; Biodegradation; Biological Sciences; Cancer; Chimeras; Control stability; Degradation; Depletion; Glutamate-ammonia ligase; Glutamine; Health services; Immunomodulation; Modulators; Multiple myeloma; Neurodegenerative diseases; Neuromodulation; Patients; Proteasomes; Proteins; Proteolysis; Resistance factors; Substrates; Teratogenicity; Thalidomide; Therapeutic targets; Ubiquitin; Ubiquitin-protein ligase
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.2111391118

Targeted protein degradation by the ubiquitin–proteasome system represents a new strategy to destroy pathogenic proteins in human diseases, including cancer and neurodegenerative diseases. The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide have revolutionized the treatment of patients with multiple myeloma (MM) and other hematologic malignancies, but almost all patients eventually develop resistance to IMiDs. CRBN, a substrate receptor of CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase, is a direct target for thalidomide teratogenicity and antitumor activity of IMiDs (now known as Cereblon E3 ligase modulators: CELMoDs). Despite recent advances in developing potent CELMoDs and CRBN-based proteolysis-targeting chimeras (PROTACs), many questions apart from clinical efficacy remain unanswered. CRBN is required for the action of IMiDs, but its protein expression levels do not correlate with intrinsic resistance to IMiDs in MM cells, suggesting other factors involved in regulating resistance to IMiDs. Our recent work revealed that the CRL4CRBN-p97 pathway is required for degradation of natural substrate glutamine synthetase (GS) and neosubstrates. Here, I show that USP15 is a key regulator of the CRL4CRBN-p97 pathway to control stability of GS and neosubstrates IKZF1, IKZF3, CK1-α, RNF166, GSPT1, and BRD4, all of which are crucial drug targets in different types of cancer. USP15 antagonizes ubiquitylation of CRL4CRBN target proteins, thereby preventing their degradation. Notably, USP15 is highly expressed in IMiD-resistant cells, and depletion of USP15 sensitizes these cells to lenalidomide. Inhibition of USP15 represents a valuable therapeutic opportunity to potentiate CELMoD and CRBN-based PROTAC therapies for the treatment of cancer.